Welcome to our dedicated page for Harvard Biosci news (Ticker: HBIO), a resource for investors and traders seeking the latest updates and insights on Harvard Biosci stock.
Harvard Bioscience, Inc. (NASDAQ: HBIO) is a life science tools company that develops, manufactures and sells technologies, products and services used in research, drug and therapy discovery, bio‑production and preclinical testing. News about Harvard Bioscience often centers on how its laboratory instruments and platforms support life science applications for academic institutions, government laboratories, pharmaceutical companies, biotechnology firms and contract research organizations.
Investors and researchers following HBIO news will find regular updates on quarterly financial results, including revenues, gross margins, net income or loss, adjusted EBITDA and cash flows from operations, as reported in the company’s earnings press releases. These announcements are typically accompanied by guidance ranges for upcoming quarters and commentary on demand trends, backlog and operational discipline.
Harvard Bioscience news also covers capital structure and financing developments. In 2025, the company reported amendments to its existing credit agreement, discussions with lenders, and the execution of a new Loan and Security Agreement with BroadOak that introduced term loans and a convertible term loan, along with associated warrants and board nomination rights. These items appear in both press releases and Form 8‑K filings and are relevant to readers tracking the company’s liquidity, debt profile and going‑concern considerations.
Another theme in HBIO coverage is corporate governance and leadership changes. The company has announced a CEO succession plan, the appointment of new independent directors, and the designation of a lead independent director. Additional news items describe board appointments linked to financing arrangements and changes in audit committee composition. Operational news has included expanded distribution agreements for laboratory equipment with a major scientific supplier and references to technologies such as pumps, spectrophotometers, BTX electroporation systems and Mesh MEA organoid platforms.
For readers interested in HBIO, this news stream provides context on the company’s financial performance, governance, listing status on Nasdaq, and its role in supplying tools for life science research and preclinical testing. Regular updates can help observers understand how Harvard Bioscience is managing its business and capital structure while serving global life science customers.
Harvard Bioscience (Nasdaq: HBIO) will announce its Q1 2021 financial results on May 6, 2021, before market opening. A conference call will follow at 8:00 a.m. ET for discussions on the earnings report. Investors can participate by calling toll-free 1 (877) 303-7611 or internationally at 1 (970) 315-0445, using conference ID # 5876756. The call will also be available via webcast on Harvard Bioscience's website. The company specializes in technologies and products for research and drug development, serving a global client base.
Harvard Bioscience reported Q4 2020 revenue of $31.0 million, returning to pre-COVID levels, aided by a 19% year-over-year increase in preclinical product revenue. Operating income rose to $2.8 million, with a GAAP operating margin of 8.9%. The company successfully refinanced its credit facility, expected to save approximately $3 million annually in interest. For 2021, Harvard anticipates revenue growth of 8% to 12% and adjusted operating margins in the mid-to-upper teens, driven by new products and improved profit mix.
Harvard Bioscience (Nasdaq: HBIO) will release its fourth-quarter financial results for the period ending December 31, 2020, before the market opens on March 10, 2021. A conference call will be held that same day at 8:00 a.m. Eastern Time to discuss the results, accessible via toll-free and international numbers. The call will also be available through a live webcast on the company's website, where financial information including the earnings release and presentation slides will be published.
Harvard Bioscience (Nasdaq: HBIO) has successfully closed a new $65 million credit facility, refinancing existing debt to enhance liquidity and reduce borrowing costs. This refinancing will yield over $2 million in annual cash interest savings starting in 2021 while providing greater operational flexibility through less restrictive covenants. The facility includes a $40 million term loan and a $25 million senior revolving credit line, aimed at supporting the company's transition into a profitable growth platform.
Harvard Bioscience (Nasdaq: HBIO) will participate in The Benchmark Company’s 9th Annual Discovery One-on-One Conference on November 18, 2020. CEO Jim Green and CFO Michael Rossi will engage in virtual meetings throughout the day. Interested investors can schedule a meeting by contacting their Benchmark representative or directly reaching out to Vince Curatola. Presentation materials will be available on the company’s investor relations page that same day at 8:00 AM ET. Harvard Bioscience specializes in technologies for drug development and serves a wide range of global customers.
Harvard Bioscience (Nasdaq: HBIO) reported Q3 2020 financial results showing improved operating income and reduced net debt year-over-year. Revenue rose sequentially to $24.0 million, supported by demand from CRO/pharma and the reopening of academic labs. Adjusted operating income was $3.6 million, with an operating margin of 14.8%. The company anticipates continued growth, forecasting mid to upper teen operating margins for the second half of 2020, driven by disciplined cost management and targeted investments.
Harvard Bioscience (Nasdaq: HBIO) will release its Q3 financial results for the period ended September 30, 2020 before the market opens on November 5, 2020. A conference call to discuss these results will take place on the same day at 8:00 a.m. ET. Participants can join the call via toll-free dial-in or access the live webcast on the company’s website. Financial information and related materials will be available in the Investor Relations section of the site.
Harvard Bioscience (Nasdaq: HBIO) announced that CEO Jim Green will present at the Singular Research Compelling Values 2020 Webinar on September 17, 2020, at 2:15 p.m. ET. The presentation will be accessible online via a registration link provided by Singular Research. A slide deck for the webinar will also be available on the company's Investor Relations page. Harvard Bioscience specializes in developing technologies and products for drug development, serving a diverse clientele ranging from academic institutions to major pharmaceutical companies globally.
Harvard Bioscience, Inc. (Nasdaq: HBIO) reported Q2 2020 results showing a revenue of $23.3 million, down from $29.6 million in Q2 2019. Despite this decline, operating income improved to $0.6 million (GAAP) from a loss of $3.3 million in Q1 2020. Adjusted operating income reached $4.1 million with a margin of 17.7%. The company reduced net debt by $2.2 million to $42.1 million. CEO Jim Green noted that cost reduction initiatives have effectively offset expected revenue declines in academic markets, enabling growth from CRO/pharma clients and improved operating margins.
Harvard Bioscience, Inc. (Nasdaq: HBIO) will release its financial results for the second quarter ending June 30, 2020, on August 5, 2020, before the market opens. A conference call will take place the same day at 8:00 a.m. Eastern Time, accessible via toll-free and international numbers with a conference ID of #4458189. The call will also be webcast on the company’s investor relations website. Harvard Bioscience specializes in technologies for fundamental research and drug development, serving academic institutions, government labs, and leading pharmaceutical firms across North America and Europe.